In xenograft models, navitoclax enhanced the efficacy of BRAF inhibitors49,68, leading to clinical trials combining this drug with BRAF/MEK inhibitors in melanoma patients (e.g., clinical trial NCT01989585). Here, BRAF is linked to melanoma.